SEC Info℠ | Home | Search | My Interests | Help | Sign In | Please Sign In | ||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/05/21 Anika Therapeutics, Inc. 10-K 12/31/20 105:11M Globenewswire Inc./FA |
Document/Exhibit Description Pages Size 1: 10-K Annual Report HTML 1.34M 6: EX-10.13D Material Contract HTML 94K 7: EX-10.13E Material Contract HTML 93K 8: EX-10.13G Material Contract HTML 85K 9: EX-10.13H Material Contract HTML 93K 2: EX-23.1 Consent of Expert or Counsel HTML 29K 3: EX-31.1 Certification -- §302 - SOA'02 HTML 35K 4: EX-31.2 Certification -- §302 - SOA'02 HTML 36K 5: EX-32.1 Certification -- §906 - SOA'02 HTML 30K 16: R1 Document And Entity Information HTML 89K 17: R2 Consolidated Balance Sheets HTML 112K 18: R3 Consolidated Balance Sheets (Parentheticals) HTML 47K 19: R4 Consolidated Statements of Operations and HTML 108K Comprehensive Income (Loss) 20: R5 Consolidated Statements of Stockholders' Equity HTML 85K 21: R6 Consolidated Statements of Cash Flows HTML 152K 22: R7 Note 1 - Nature of Business HTML 35K 23: R8 Note 2 - Summary of Significant Accounting HTML 118K Policies 24: R9 Note 3 - Business Combinations HTML 100K 25: R10 Note 4 - Fair Value Measurements HTML 90K 26: R11 Note 5 - Inventories HTML 44K 27: R12 Note 6 - Property and Equipment HTML 44K 28: R13 Note 7 - Acquired Intangible Assets, Net HTML 85K 29: R14 Note 8 - Goodwill HTML 47K 30: R15 Note 9 - Leases HTML 79K 31: R16 Note 10 - Accrued Expenses HTML 43K 32: R17 Note 11 - Revolving Credit Agreement HTML 35K 33: R18 Note 12 - Commitments and Contingencies HTML 34K 34: R19 Note 13 - Revenue by Product Group, by Significant HTML 87K Customer and by Geographic Location; Geographic Information 35: R20 Note 14 - Equity Incentive Plan HTML 108K 36: R21 Note 15 - Employee Benefit Plan HTML 33K 37: R22 Note 16 - Accelerated Share Repurchases HTML 36K 38: R23 Note 17 - Income Taxes HTML 120K 39: R24 Note 18 - Earnings Per Share ("Eps") HTML 43K 40: R25 Note 19 - Quarterly Financial Data (Unaudited) HTML 67K 41: R26 Significant Accounting Policies (Policies) HTML 171K 42: R27 Note 2 - Summary of Significant Accounting HTML 52K Policies (Tables) 43: R28 Note 3 - Business Combinations (Tables) HTML 81K 44: R29 Note 4 - Fair Value Measurements (Tables) HTML 85K 45: R30 Note 5 - Inventories (Tables) HTML 42K 46: R31 Note 6 - Property and Equipment (Tables) HTML 42K 47: R32 Note 7 - Acquired Intangible Assets, Net (Tables) HTML 79K 48: R33 Note 8 - Goodwill (Tables) HTML 39K 49: R34 Note 9 - Leases (Tables) HTML 76K 50: R35 Note 10 - Accrued Expenses (Tables) HTML 41K 51: R36 Note 13 - Revenue by Product Group, by Significant HTML 86K Customer and by Geographic Location; Geographic Information (Tables) 52: R37 Note 14 - Equity Incentive Plan (Tables) HTML 102K 53: R38 Note 17 - Income Taxes (Tables) HTML 115K 54: R39 Note 18 - Earnings Per Share ("Eps") (Tables) HTML 40K 55: R40 Note 19 - Quarterly Financial Data (Unaudited) HTML 65K (Tables) 56: R41 Note 2 - Summary of Significant Accounting HTML 72K Policies (Details Textual) 57: R42 Note 2 - Summary of Significant Accounting HTML 39K Policies - Allowance for Doubtful Accounts (Details) 58: R43 Note 2 - Summary of Significant Accounting HTML 39K Policies - Estimated Useful Lives of Property and Equipment (Details) 59: R44 Note 3 - Business Combinations (Details Textual) HTML 74K 60: R45 Note 3 - Business Combinations - Consideration HTML 41K Transferred (Details) 61: R46 Note 3 - Business Combinations - Fair Value of Net HTML 74K Assets Acquired (Details) 62: R47 Note 3 - Business Combinations - Intangible Assets HTML 43K Acquired (Details) 63: R48 Note 3 - Business Combinations - Pro Forma HTML 32K Information (Details) 64: R49 Note 4 - Fair Value Measurements (Details Textual) HTML 68K 65: R50 Note 4 - Fair Value Measurements - Fair Value of HTML 62K Financial Instruments (Details) 66: R51 Note 4 - Fair Value Measurements - Contingent HTML 38K Consideration (Details) 67: R52 Note 5 - Inventories (Details Textual) HTML 34K 68: R53 Note 5 - Inventories - Summary of Inventories HTML 41K (Details) 69: R54 Note 6 - Property and Equipment (Details Textual) HTML 30K 70: R55 Note 6 - Property and Equipment - Property and HTML 43K Equipment at Cost (Details) 71: R56 Note 7 - Acquired Intangible Assets, Net (Details HTML 50K Textual) 72: R57 Note 7 - Acquired Intangible Assets, Net - Summary HTML 63K of Intangible Assets (Details) 73: R58 Note 8 - Goodwill (Details Textual) HTML 32K 74: R59 Note 8 - Goodwill - Changes in the Carrying Value HTML 38K of Goodwill (Details) 75: R60 Note 9 - Leases (Details Textual) HTML 32K 76: R61 Note 9 - Leases - Lease Expense and Other HTML 58K Information (Details) 77: R62 Note 9 - Leases - Future Minimum Rental Payments HTML 95K for Operating Leases (Details) 78: R63 Note 10 - Accrued Expenses - Summary of Accrued HTML 45K Expenses (Details) 79: R64 Note 11 - Revolving Credit Agreement (Details HTML 63K Textual) 80: R65 Note 12 - Commitments and Contingencies (Details HTML 30K Textual) 81: R66 Note 13 - Revenue by Product Group, by Significant HTML 35K Customer and by Geographic Location; Geographic Information (Details Textual) 82: R67 Note 13 - Revenue by Product Group, by Significant HTML 50K Customer and by Geographic Location; Geographic Information - Product Revenue by Product Group (Details) 83: R68 Note 13 - Revenue by Product Group, by Significant HTML 47K Customer and by Geographic Location; Geographic Information - Total Revenue by Geographic Location (Details) 84: R69 Note 13 - Revenue by Product Group, by Significant HTML 34K Customer and by Geographic Location; Geographic Information - Net Tangible Long-lived Assets by Principal Geographic Areas (Details) 85: R70 Note 14 - Equity Incentive Plan (Details Textual) HTML 131K 86: R71 Note 14 - Equity Incentive Plan - Granted and HTML 48K Exercised Stock-based Compensation Awards (Details) 87: R72 Note 14 - Equity Incentive Plan - Stock Options HTML 50K and SAR's Activity (Details) 88: R73 Note 14 - Equity Incentive Plan - Summary of HTML 41K Exercisable Options and SAR's (Details) 89: R74 Note 14 - Equity Incentive Plan - Restricted Stock HTML 50K Activity (Details) 90: R75 Note 14 - Equity Incentive Plan - Assumptions Used HTML 42K to Estimate Fair Value of Stock Options and Stock Appreciation Rights (Details) 91: R76 Note 14 - Equity Incentive Plan - Total HTML 36K Stock-based Compensation Expense (Details) 92: R77 Note 15 - Employee Benefit Plan (Details Textual) HTML 33K 93: R78 Note 16 - Accelerated Share Repurchases (Details HTML 72K Textual) 94: R79 Note 17 - Income Taxes (Details Textual) HTML 59K 95: R80 Note 17 - Income Taxes - Components of Income HTML 63K Before Taxes and Provision for (Benefit from) Income Taxes (Details) 96: R81 Note 17 - Income Taxes - Significant Components of HTML 62K Company's Deferred Tax Assets and Liabilities (Details) 97: R82 Note 17 - Income Taxes - Reconciliation Between HTML 52K U.S. Federal Statutory Rate and Effective Rate (Details) 98: R83 Note 18 - Earnings Per Share ("Eps") (Details HTML 34K Textual) 99: R84 Note 18 - Earnings Per Share ("EPS") - Basic and HTML 38K Diluted Earnings Per Share (Details) 100: R85 Note 19 - Quarterly Financial Data (Unaudited) HTML 34K (Details Textual) 101: R86 Note 19 - Quarterly Financial Data (Unaudited) - HTML 67K Quarterly Financial Data (Unaudited) (Details) 103: XML IDEA XML File -- Filing Summary XML 199K 15: XML XBRL Instance -- anik20201231_10k_htm XML 2.55M 102: EXCEL IDEA Workbook of Financial Reports XLSX 118K 11: EX-101.CAL XBRL Calculations -- anik-20201231_cal XML 186K 12: EX-101.DEF XBRL Definitions -- anik-20201231_def XML 1.68M 13: EX-101.LAB XBRL Labels -- anik-20201231_lab XML 1.36M 14: EX-101.PRE XBRL Presentations -- anik-20201231_pre XML 1.72M 10: EX-101.SCH XBRL Schema -- anik-20201231 XSD 250K 104: JSON XBRL Instance as JSON Data -- MetaLinks 456± 766K 105: ZIP XBRL Zipped Folder -- 0001171843-21-001573-xbrl Zip 374K
This ‘10-K’ Filing | Date | Other Filings | ||
---|---|---|---|---|
Filed on: | 3/5/21 | |||
For Period end: | 12/31/20 | 10-K/A | ||
10/15/20 | ||||
9/30/20 | 10-Q | |||
6/30/20 | 10-Q | |||
3/31/20 | 10-Q, 10-Q/A | |||
2/3/20 | 8-K, 8-K/A | |||
1/24/20 | 8-K, 8-K/A | |||
12/31/19 | 10-K | |||
12/31/18 | 10-K | |||
List all Filings |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/15/24 Anika Therapeutics, Inc. 10-K 12/31/23 90:9.1M Globenewswire Inc./FA 3/16/23 Anika Therapeutics, Inc. 10-K 12/31/22 97:10M Globenewswire Inc./FA 3/11/22 Anika Therapeutics, Inc. 10-K 12/31/21 105:25M Globenewswire Inc./FA 5/07/21 Anika Therapeutics, Inc. 10-Q 3/31/21 67:5.1M Globenewswire Inc./FA 4/26/21 Anika Therapeutics, Inc. 10-K/A 12/31/20 100:10M Globenewswire Inc./FA |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 8/05/20 Anika Therapeutics, Inc. 8-K:5,7,9 8/05/20 3:95K Globenewswire Inc./FA 6/18/20 Anika Therapeutics, Inc. 8-K:5,9 6/16/20 2:194K Globenewswire Inc./FA 5/22/20 Anika Therapeutics, Inc. 10-Q 3/31/20 77:4.8M Globenewswire Inc./FA 4/29/20 Anika Therapeutics, Inc. 8-K:1,5,7,9 4/23/20 3:147K Globenewswire Inc./FA 3/06/20 Anika Therapeutics, Inc. 10-K 12/31/19 98:6.4M Globenewswire Inc./FA 3/02/20 Anika Therapeutics, Inc. 8-K:5,9 2/25/20 2:53K Globenewswire Inc./FA 1/07/20 Anika Therapeutics, Inc. 8-K:1,9 1/04/20 3:1.2M Globenewswire Inc./FA 7/26/19 Anika Therapeutics, Inc. 10-Q 6/30/19 68:3.4M Globenewswire Inc./FA 7/10/19 Anika Therapeutics, Inc. 8-K:5 7/05/19 3:131K Globenewswire Inc./FA 6/20/19 Anika Therapeutics, Inc. 8-K:5,9 6/18/19 2:185K Globenewswire Inc./FA 4/12/19 Anika Therapeutics, Inc. 8-K:5,9 4/09/19 5:230K Globenewswire Inc./FA 7/31/18 Anika Therapeutics, Inc. 10-Q 6/30/18 62:2.9M Globenewswire Inc./FA 6/06/18 Anika Therapeutics, Inc. 8-K:5,8,9 5/31/18 4:323K Globenewswire Inc./FA 3/08/18 Anika Therapeutics, Inc. 8-K:5,8,9 3/02/18 4:141K Globenewswire Inc./FA 10/27/17 Anika Therapeutics, Inc. 10-Q 9/30/17 66:4.1M Globenewswire Inc./FA 7/27/17 Anika Therapeutics, Inc. 8-K:5,7,9 7/27/17 3:116K Business Wire/FA 6/19/17 Anika Therapeutics, Inc. 8-K:5,9 6/13/17 6:320K Globenewswire Inc./FA 2/24/17 Anika Therapeutics, Inc. 10-K 12/31/16 86:5.9M Globenewswire Inc./FA 5/03/16 Anika Therapeutics, Inc. 10-Q 3/31/16 65:2.6M Globenewswire Inc./FA 10/14/15 Anika Therapeutics, Inc. 8-K:1,9 10/09/15 2:252K Business Wire/FA 5/05/14 Anika Therapeutics, Inc. 10-Q 3/31/14 61:3.5M Globenewswire Inc./FA 12/22/11 Anika Therapeutics, Inc. 8-K:1,9 12/21/11 3:832K Business Wire/FA 6/10/11 Anika Therapeutics, Inc. 8-K:5,9 6/07/11 2:108K Business Wire/FA 3/16/11 Anika Therapeutics, Inc. 10-K 12/31/10 10:2M Business Wire/FA 1/06/10 Anika Therapeutics, Inc. 8-K:1,2,3,912/30/09 7:1.4M Business Wire/FA 9/14/09 Anika Therapeutics, Inc. 8-K:5 9/10/09 3:108K Business Wire/FA 10/22/08 Anika Therapeutics, Inc. 8-K:5 10/17/08 3:249K Business Wire/FA 3/12/08 Anika Therapeutics, Inc. 10-K 12/31/07 8:784K Toppan Merrill-FA 2/06/08 Anika Therapeutics, Inc. 8-K:1,5,9 1/31/08 4:794K Toppan Merrill/FA 1/10/07 Anika Therapeutics, Inc. 8-K:1,2,9 1/04/07 2:489K Toppan Merrill/FA 10/05/04 Anika Therapeutics, Inc. 8-K:1,5,9 9/29/04 6:201K Toppan Merrill/FA 3/30/04 Anika Therapeutics, Inc. 10-K 12/31/03 8:741K Toppan Merrill-FA |